Home » Catalent to add 90 new jobs in Winchester

Catalent to add 90 new jobs in Winchester

Drug maker planning $35 million expansion

WINCHESTER, Ky. (June 12, 2013) – Catalent Pharma Solutions LLC plans to spend $35 million to expand its Winchester operations and add 90 jobs. Gov. Steve Beshear on Wednesday joined local and company officials in Winchester to make the announcement and break ground on the project.

Gov. Steve Beshear on Wednesday joined local officials to break ground on Catalent Pharma Solutions' expansion in Winchester.
Gov. Steve Beshear on Wednesday joined local officials to break ground on Catalent Pharma Solutions’ expansion in Winchester.

To meet increased industry demand, the company is adding 80,000 s.f. to its current 100,000-s.f. facility on Enterprise Drive in Winchester.

“Catalent is making tremendous strides in Winchester, and we’re excited to see such success for a global company in the Commonwealth,” Beshear said. “The numbers speak for themselves, with 90 new jobs and $35 million in investment, but this also shows the level of confidence that Catalent has in Kentucky’s high quality workforce.”

Catalent is a global leader in development solutions and advanced drug delivery technologies, providing worldwide clinical and commercial supply capabilities for drugs, biologics and consumer health products. The company employs approximately 8,500 people, including more than 1,000 scientists, at nearly 30 facilities on five continents.

Opened in 1992, the Winchester plant currently employs more than 300 people and produces a variety of over-the-counter and prescription drugs in tablet, capsules and powders. The facility has launched more than 100 products for Catalent’s pharmaceutical and consumer health customers. Catalent expects to complete the expansion of the facility by October 2014.

“Catalent is a fully integrated formulation, regulatory, and manufacturing solutions partner, helping pharmaceutical and consumer healthcare companies differentiate their products and reach markets faster,” said John Chiminski, president and CEO of Catalent Pharma Solutions.

“Catalent has been present at this site for over 20 years developing and manufacturing important medicines,” said Steve Havel, general manager of Catalent’s Winchester facility. “Our commitment to Kentucky is illustrated by the expansion of our Winchester facility, which will provide our customers with more capabilities to help develop and manufacture new products.”

The Kentucky Economic Development Finance Authority (KEDFA) preliminarily approved the company for tax incentives up to $2 million through the Kentucky Business Investment program. The performance-based incentive allows a company to keep a portion of its investment over the term of the agreement through corporate income tax credits and wage assessments by meeting job and investment targets.

KEDFA also approved Catalent for tax benefits up to $860,000 through the Kentucky Enterprise Initiative Act, which allows approved companies to recoup Kentucky sales and use tax on construction costs, building fixtures, equipment used in research and development and electronic processing equipment.